Cargando…

Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature

Treatment of lung cancer has been revolutionized with development of drugs that target key driver mutations and immune checkpoints. Until recently, it was believed that these driver mutations are mutually exclusive. However, few reports have emerged citing the presence of both mutations either synch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thumallapally, Nishitha, Parylo, Sara, Vennepureddy, Adarsh, Ibrahim, Uroosa, Sokoloff, Alisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942208/ https://www.ncbi.nlm.nih.gov/pubmed/29760833 http://dx.doi.org/10.14740/wjon1090e

Ejemplares similares

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
por: Vennepureddy, Adarsh, et al.
Publicado: (2016)

Correction: Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia
por: Parylo, Sara, et al.
Publicado: (2017)

Vulvar Cancer with Cutaneous and Breast Metastases
por: Adhikari, Nawaraj, et al.
Publicado: (2021)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Esophageal Granular Cell Tumor: A Case Report and Review of Literature
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

A Case of Vancomycin-Induced Immune Thrombocytopenia
por: MacDougall, Kira N, et al.
Publicado: (2020)

Rivaroxaban-Induced Nontraumatic Spinal Subdural Hematoma: An Uncommon Yet Life-Threatening Complication
por: Zaarour, Mazen, et al.
Publicado: (2015)

Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA
por: Thumallapally, Nishitha, et al.
Publicado: (2017)

Erratum to: Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA
por: Thumallapally, Nishitha, et al.
Publicado: (2017)

Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab
por: Ibrahim, Uroosa, et al.
Publicado: (2017)

Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia
por: Parylo, Sara, et al.
Publicado: (2017)

A Rare Case of Aggressive Systemic Mastocytosis With Skeletal Osteosclerotic Lesions on Presentation: A Diagnostic Conundrum
por: Ghorpade, Rina, et al.
Publicado: (2022)

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma
por: Park, Jangchul, et al.
Publicado: (2016)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
por: Wang, Huijuan, et al.
Publicado: (2019)

Primary plasma cell leukemia: A case report and review of the literature
por: Ngu, Sam, et al.
Publicado: (2019)

Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature
por: Vennepureddy, Adarsh, et al.
Publicado: (2015)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status
por: Han, Xiaoyu, et al.
Publicado: (2020)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Prognostic and predictive markers in glioblastoma and ALK overexpression
por: Kim, Jang-Hee
Publicado: (2021)

Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations
por: Wang, H.-Y., et al.
Publicado: (2022)

Synchronous Diagnosis of Multiple Myeloma, Breast Cancer, and Monoclonal B-Cell Lymphocytosis on Initial Presentation
por: Vennepureddy, A., et al.
Publicado: (2016)

Primary Pulmonary Lymphoma and Synchronous Cecal Adenocarcinoma: A Rare Occurrence
por: Saqib, Amina, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations
por: Lim, Jeong Uk, et al.
Publicado: (2015)

Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer
por: Yamasaki, Masahiro, et al.
Publicado: (2017)

ALK Negative Inflammatory Myofibroblastic Tumor Synchronous with Classical Hodgkin Lymphoma
por: Sandoval, Letícia, et al.
Publicado: (2019)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

ALK-Negative Anaplastic Large Cell Lymphoma Presenting as Disseminated Intravascular Coagulation and Hemophagocytic Lymphohistiocytosis: A Potentially Fatal Presentation
por: Ibrahim, Uroosa, et al.
Publicado: (2018)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
por: Andraos, Elissa, et al.
Publicado: (2021)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a08u1fhphhms414msgn5udmfm3